Executive Management

Throughout her 25+ years of industry experience, Ms. Yee has been featured in a number of publications, including the Boston Globe, the Economist, Fortune Magazine, IDG journals, Investor’s Business Daily and most recently, Forbes Asia. She is one of Fortune’s Top 10 Most Powerful Women in 2012, the recipient of an international Stevie Award for Best Asian Entrepreneur for Women in Business, a Top 25 Globalization Executive by Globalization Today, and was identified by CNN Money as one of technology’s 36 most powerful disrupters.

Ms. Yee has been recognized for her many contributions in the sphere of education including to the Johns Hopkins US-China Studies Nanjing Center for its cross-cultural program as well as to Michelle Obama’s Let Girls Learn initiative, where CSOFT worked on translating enhanced gender training literature for the Peace Corps from English into multiple languages, helping the Obama Administration reach 62 million girls worldwide.

In June 2016, Ms. Yee led CSOFT into a partnership with the Shenzhen Municipal Government and launched the Shenzhen 100 research report, which assists the government in implementing effective policies to support global market strategies. Ms. Yee sits on Dexter Southfield School’s Academic Board, and she is a Committee member of A Taste of Ginger, an event hosted by the world-renowned Joslin Center, for promoting awareness and education in support of the Asian American Diabetes Initiative.

He joined CSOFT as an Italian QA Specialist/Translator, position that he covered for five years after which he has started to cover more managerial and operational roles. Prior to joining CSOFT, Diego worked as a Tech Consultant for two years at a leading global mobile company.

Entering the healthcare market in 2010, Di first worked for BGI (Beijing Genomics Institute), one of the largest biotechnology firms in China. Her work at BGI took her to Belgium and Germany as the Business Development Manager, calling on clinical institutions, medical schools, and pharmaceutical companies.

These projects included: driving the marketing of Zhejiang Whiteson’s Latamoxef (a broad- spectrum beta-lactam antibiotic); facilitating the rapid sales growth (over three years) of Hainan Tianhuang and its nearly 1 billion RMB in revenues after the overall acquisition; assisting Henan Shuaiguang as it became the second company in China to market Clopidogrel there; participating in the formulation of different dose strengths to achieve a greater market success; and indirectly helping Lepu Medical and Gloria Pharmaceuticals to achieve their goals.

Dr. Wang entered the field of translational research in 2013. He headed the Foshan Industrial Technology Research Institute of the Chinese Academy of Sciences’ pharmaceutical project and established strong commercialization partnerships with the Chinese Academy of Sciences and Peking University.

Dr. Wang holds a degree in Pharmacy  from the Peking University Health Science Center and was Vice Chairman of the Student Union at the Center.